Publication:
Free Text: Modular nanotransporters: a multipurpose in vivo working platform for targeted drug delivery.


abstract

BACKGROUND:

Modular nanotransporters (MNT) are recombinant multifunctional polypeptides created to exploit a cascade of cellular processes, initiated with membrane receptor recognition to deliver selective short-range and highly cytotoxic therapeutics to the cell nucleus. This research was designed for in vivo concept testing for this drug delivery platform using two modular nanotransporters, one targeted to the α-melanocyte-stimulating hormone (αMSH) receptor overexpressed on melanoma cells and the other to the epidermal growth factor (EGF) receptor overexpressed on several cancers, including glioblastoma, and head-and-neck and breast carcinoma cells.

METHODS:

In vivo targeting of the modular nanotransporter was determined by immuno-fluorescence confocal laser scanning microscopy and by accumulation of (125)I-labeled modular nanotransporters. The in vivo therapeutic effects of the modular nanotransporters were assessed by photodynamic therapy studies, given that the cytotoxicity of photosensitizers is critically dependent on their delivery to the cell nucleus.

RESULTS:

Immunohistochemical analyses of tumor and neighboring normal tissues of mice injected with multifunctional nanotransporters demonstrated preferential uptake in tumor tissue, particularly in cell nuclei. With (125)I-labeled MNT{αMSH}, optimal tumor:muscle and tumor:skin ratios of 8:1 and 9.8:1, respectively, were observed 3 hours after injection in B16-F1 melanoma-bearing mice. Treatment with bacteriochlorin p-MNT{αMSH} yielded 89%-98% tumor growth inhibition and a two-fold increase in survival for mice with B16-F1 and Cloudman S91 melanomas. Likewise, treatment of A431 human epidermoid carcinoma-bearing mice with chlorin e(6)- MNT{EGF} resulted in 94% tumor growth inhibition compared with free chlorin e(6), with 75% of animals surviving at 3 months compared with 0% and 20% for untreated and free chlorin e(6)-treated groups, respectively.

CONCLUSION:

The multifunctional nanotransporter approach provides a new in vivo functional platform for drug development that could, in principle, be applicable to any combination of cell surface receptor and agent (photosensitizers, oligonucleotides, radionuclides) requiring nuclear delivery to achieve maximum effectiveness.

Related Articles
Therapeutic efficacy of a 188Re-labeled alpha-melanocyte-stimulating hormone peptide analog in murine and human melanoma-bearing mouse models.
J Nucl Med. 2005
Therapeutic efficacy of a 188Re-labeled alpha-melanocyte-stimulating hormone peptide analog in murine and human melanoma-bearing mouse models.
Miao Y, Owen NK, Fisher DR, Hoffman TJ, Quinn TP. J Nucl Med. 2005 Jan; 46(1):121-9.
Tissue uptake study and photodynamic therapy of melanoma-bearing mice with a nontoxic, effective chlorin.
ChemMedChem. 2011
Tissue uptake study and photodynamic therapy of melanoma-bearing mice with a nontoxic, effective chlorin.
Dąbrowski JM, Krzykawska M, Arnaut LG, Pereira MM, Monteiro CJ, Simões S, Urbańska K, Stochel G. ChemMedChem. 2011 Sep 5; 6(9):1715-26. Epub 2011 Jul 5.
Melanoma-targeting properties of (99m)technetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues.
Cancer Res. 2000
Melanoma-targeting properties of (99m)technetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues.
Chen J, Cheng Z, Hoffman TJ, Jurisson SS, Quinn TP. Cancer Res. 2000 Oct 15; 60(20):5649-58.
Review Modular nanotransporters of anticancer drugs conferring cell specificity and higher efficiency.
Biochemistry (Mosc). 2009
Review Modular nanotransporters of anticancer drugs conferring cell specificity and higher efficiency.
Sobolev AS. Biochemistry (Mosc). 2009 Dec; 74(13):1567-74.
Review Radiolabeled alpha-melanocyte-stimulating hormone analogs for receptor-mediated targeting of melanoma: from tritium to indium.
J Mol Recognit. 2003
Review Radiolabeled alpha-melanocyte-stimulating hormone analogs for receptor-mediated targeting of melanoma: from tritium to indium.
Eberle AN, Froidevaux S. J Mol Recognit. 2003 Sep-Oct; 16(5):248-54.